Hanmi Pharm Co Ltd (128940) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩42.02 Billion ≈ $28.48 Million USD) by net assets (₩1.35 Trillion ≈ $911.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hanmi Pharm Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Hanmi Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Hanmi Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hanmi Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hanmi Pharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crescent Energy Co
NYSE:CRGY
|
0.072x |
|
General de Galerias Comerciales SOCIMI S.A.
MC:GGC
|
0.190x |
|
ASSECO POLAND GDR/1 ZY 1
F:SFBG
|
N/A |
|
Aris Mining Corporation
TO:ARIS
|
0.101x |
|
Nuode Investment Co Ltd
SHG:600110
|
0.013x |
|
Holmen AB (publ)
ST:HOLM-B
|
0.023x |
|
VEON Ltd
NASDAQ:VEON
|
0.196x |
|
Jiangsu Dingsheng New Material Joint-Stock Co Ltd
SHG:603876
|
0.012x |
Annual Cash Flow Conversion Efficiency for Hanmi Pharm Co Ltd (2010–2024)
The table below shows the annual cash flow conversion efficiency of Hanmi Pharm Co Ltd from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Hanmi Pharm Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩1.24 Trillion ≈ $840.84 Million |
₩193.49 Billion ≈ $131.12 Million |
0.156x | -20.77% |
| 2023-12-31 | ₩1.10 Trillion ≈ $745.60 Million |
₩216.54 Billion ≈ $146.74 Million |
0.197x | +22.41% |
| 2022-12-31 | ₩1.01 Trillion ≈ $683.94 Million |
₩162.27 Billion ≈ $109.97 Million |
0.161x | -26.09% |
| 2021-12-31 | ₩928.26 Billion ≈ $629.07 Million |
₩201.92 Billion ≈ $136.84 Million |
0.218x | +19.42% |
| 2020-12-31 | ₩831.89 Billion ≈ $563.76 Million |
₩151.53 Billion ≈ $102.69 Million |
0.182x | +1103.39% |
| 2019-12-31 | ₩822.26 Billion ≈ $557.23 Million |
₩12.45 Billion ≈ $8.43 Million |
0.015x | -54.02% |
| 2018-12-31 | ₩789.26 Billion ≈ $534.87 Million |
₩25.98 Billion ≈ $17.61 Million |
0.033x | +141.47% |
| 2017-12-31 | ₩792.42 Billion ≈ $537.01 Million |
₩-62.91 Billion ≈ $-42.63 Million |
-0.079x | -114.12% |
| 2016-12-31 | ₩734.52 Billion ≈ $497.77 Million |
₩412.97 Billion ≈ $279.86 Million |
0.562x | +311.70% |
| 2015-12-31 | ₩744.81 Billion ≈ $504.75 Million |
₩101.71 Billion ≈ $68.93 Million |
0.137x | +345.18% |
| 2014-12-31 | ₩589.25 Billion ≈ $399.32 Million |
₩-32.82 Billion ≈ $-22.24 Million |
-0.056x | -129.98% |
| 2013-12-31 | ₩462.92 Billion ≈ $313.71 Million |
₩85.99 Billion ≈ $58.28 Million |
0.186x | +20.19% |
| 2012-12-31 | ₩409.34 Billion ≈ $277.41 Million |
₩63.27 Billion ≈ $42.88 Million |
0.155x | -4.64% |
| 2011-12-31 | ₩378.22 Billion ≈ $256.32 Million |
₩61.30 Billion ≈ $41.54 Million |
0.162x | +178.39% |
| 2010-12-31 | ₩325.38 Billion ≈ $220.50 Million |
₩18.94 Billion ≈ $12.84 Million |
0.058x | -- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more